Literature DB >> 10027400

Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors.

M Nakada1, H Nakamura, E Ikeda, N Fujimoto, J Yamashita, H Sato, M Seiki, Y Okada.   

Abstract

Three different membrane-type matrix metalloproteinases (MT1-, MT2-, and MT3-MMPs) are known to activate in vitro the zymogen of MMP-2 (pro-MMP-2, progelatinase A), which is one of the key MMPs in invasion and metastasis of various cancers. In the present study, we have examined production and activation of pro-MMP-2, expression of MT1-, MT2-, and MT3-MMPs and their correlation with pro-MMP-2 activation, and localization of MMP-2, MT1-MMP, and MT2-MMP in human astrocytic tumors. The sandwich enzyme immunoassay demonstrates that the production levels of pro-MMP-2 in the anaplastic astrocytomas and glioblastomas are significantly higher than that in the low-grade astrocytomas (P<0.05 and P<0.01, respectively), metastatic brain tumors (P<0.05), or normal brains (P<0.01). Gelatin zymography indicates that the pro-MMP-2 activation ratio is significantly higher in the glioblastomas than in other astrocytic tumors (P<0.01), metastatic brain tumors (P<0.01), and normal brains (P<0.01). The quantitative reverse transcription polymerase chain reaction analyses demonstrate that MT1-MMP and MT2-MMP are expressed predominantly in glioblastoma tissues (17/17 and 12/17 cases, respectively), and their expression levels increase significantly as tumor grade increases. MT3-MMP is detectable in both astrocytic tumor and normal brain tissues, but the mean expression level is approximately 50-fold lower compared with that of MT1-MMP and MT2-MMP in the glioblastomas. The activation ratio of pro-MMP-2 correlates directly with the expression levels of MT1-MMP and MT2-MMP but not MT3-MMP. In situ hybridization indicates that neoplastic astrocytes express MT1-MMP and MT2-MMP in the glioblastoma tissues (5/5 cases and 5/5 cases, respectively). Immunohistochemically, MT1-MMP and MT2-MMP are localized to the neoplastic astrocytes in glioblastoma samples (17/17 cases and 12/17 cases, respectively), which are also positive for MMP-2. In situ zymography shows gelatinolytic activity in the glioblastoma tissues but not in the normal brain tissues. These results suggest that both MT1-MMP and MT2-MMP play a key role in the activation of pro-MMP-2 in the human malignant astrocytic tumors and that the gelatinolytic activity is involved in the astrocytic tumor invasion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027400      PMCID: PMC1850004          DOI: 10.1016/S0002-9440(10)65288-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties.

Authors:  Y Okada; T Morodomi; J J Enghild; K Suzuki; A Yasui; I Nakanishi; G Salvesen; H Nagase
Journal:  Eur J Biochem       Date:  1990-12-27

Review 2.  Tumor cell interactions with the extracellular matrix during invasion and metastasis.

Authors:  W G Stetler-Stevenson; S Aznavoorian; L A Liotta
Journal:  Annu Rev Cell Biol       Date:  1993

3.  Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas.

Authors:  A Okada; J P Bellocq; N Rouyer; M P Chenard; M C Rio; P Chambon; P Basset
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

4.  Expression of membrane-type matrix metalloproteinase in human gastric carcinomas.

Authors:  H Nomura; H Sato; M Seiki; M Mai; Y Okada
Journal:  Cancer Res       Date:  1995-08-01       Impact factor: 12.701

5.  Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B) in osteoclasts: implications for bone resorption.

Authors:  Y Okada; K Naka; K Kawamura; T Matsumoto; I Nakanishi; N Fujimoto; H Sato; M Seiki
Journal:  Lab Invest       Date:  1995-03       Impact factor: 5.662

6.  A matrix metalloproteinase expressed on the surface of invasive tumour cells.

Authors:  H Sato; T Takino; Y Okada; J Cao; A Shinagawa; E Yamamoto; M Seiki
Journal:  Nature       Date:  1994-07-07       Impact factor: 49.962

7.  A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies.

Authors:  N Fujimoto; N Mouri; K Iwata; E Ohuchi; Y Okada; T Hayakawa
Journal:  Clin Chim Acta       Date:  1993-11-30       Impact factor: 3.786

8.  Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors.

Authors:  H Autio-Harmainen; T Karttunen; T Hurskainen; M Höyhtyä; A Kauppila; K Tryggvason
Journal:  Lab Invest       Date:  1993-09       Impact factor: 5.662

9.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.

Authors:  Z S Galis; G K Sukhova; M W Lark; P Libby
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

10.  Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human urothelial carcinomas.

Authors:  Y Kitagawa; K Kunimi; H Ito; H Sato; T Uchibayashi; Y Okada; M Seiki; M Namiki
Journal:  J Urol       Date:  1998-10       Impact factor: 7.450

View more
  56 in total

Review 1.  Multi-agent cytostatic treatment of 'low-grade' gliomas.

Authors:  M E Linskey
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

2.  Variability in melanoma metalloproteinase expression profiling.

Authors:  Orsi Giricz; Janelle L Lauer; Gregg B Fields
Journal:  J Biomol Tech       Date:  2010-12

3.  Glioma expansion in collagen I matrices: analyzing collagen concentration-dependent growth and motility patterns.

Authors:  L J Kaufman; C P Brangwynne; K E Kasza; E Filippidi; V D Gordon; T S Deisboeck; D A Weitz
Journal:  Biophys J       Date:  2005-04-22       Impact factor: 4.033

Review 4.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

5.  Upregulated β1-6 branch N-glycan marks early gliomagenesis but exhibited biphasic expression in the progression of astrocytic glioma.

Authors:  Arshad Ahmed Padhiar; Jianhui Fan; Ying Tang; Juanhan Yu; Shujing Wang; Linhua Liu; Bachir Niang; Max Efui Annani-Akollor; Lifen Wang; Qi Wang; Jianing Zhang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

6.  Inhibiting Matrix Metalloproteinase-2 Activation by Perturbing Protein-Protein Interactions Using a Cyclic Peptide.

Authors:  Priyanka Sarkar; Zhonghan Li; Wendan Ren; Siwen Wang; Shiqun Shao; Jianan Sun; Xiaodong Ren; Nicole G Perkins; Zhili Guo; Chia-En A Chang; Jikui Song; Min Xue
Journal:  J Med Chem       Date:  2020-06-18       Impact factor: 7.446

7.  Red-shifted fluorescent proteins monitor enzymatic activity in live HT-1080 cells with fluorescence lifetime imaging microscopy (FLIM).

Authors:  J P Eichorst; R M Clegg; Y Wang
Journal:  J Microsc       Date:  2012-10       Impact factor: 1.758

8.  Differences between scirrhous and non-scirrhous human gastric carcinomas from the aspect of proMMP-2 activation regulated by TIMP-3.

Authors:  Takeyoshi Yokoyama; Hiroyuki Nakamura; Yoshihide Otani; Tetsuro Kubota; Noboru Fujimoto; Motoharu Seiki; Masaki Kitajima; Yasunori Okada
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  Comparative expression pattern of Matrix-Metalloproteinases in human glioblastoma cell-lines and primary cultures.

Authors:  Carsten Hagemann; Jelena Anacker; Stefanie Haas; Daniela Riesner; Beate Schömig; Ralf-Ingo Ernestus; Giles H Vince
Journal:  BMC Res Notes       Date:  2010-11-10

10.  Identification of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation in association with neuroblastoma progression.

Authors:  Carine Nyalendo; Hervé Sartelet; Stéphane Barrette; Shigeru Ohta; Denis Gingras; Richard Béliveau
Journal:  BMC Cancer       Date:  2009-12-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.